Sec Form 4 Filing - Kummeth Charles R. @ BIO-TECHNE Corp - 2019-12-23

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kummeth Charles R. 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 614 MCKINLEY PLACE NE 3. Date of Earliest Transaction (MM/DD/YY) 12/23/2019 (Street) MINNEAPOLIS, MN55413 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12/23/2019 M 659 A $ 67.46 130,648 ( 1 ) D Common Stock 12/23/2019 S( 2 ) 659 D $ 222.0802 ( 3 ) 129,989 ( 1 ) D Common Stock 12/24/2019 M 471 A $ 67.46 130,460 ( 1 ) D Common Stock 12/24/2019 S( 2 ) 471 D $ 222.1834 ( 4 ) 129,989 ( 1 ) D Common Stock 100 I By Step-Son Common Stock 100 I By Step-Daughter

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to Buy) $ 67.46 12/23/2019 M 659 ( 5 ) 04/01/2020 Common Stock 659 $ 0 38,689 D Stock Options (Right to Buy) $ 67.46 12/24/2019 M 471 ( 5 ) 04/01/2020 Common Stock 471 $ 0 38,218 D Stock Options (Right to Buy) $ 86.25 ( 5 ) 04/01/2021 Common Stock 46,316 46,316 D Stock Options (Right to Buy) $ 94.35 ( 5 ) 08/12/2021 Common Stock 66,849 66,849 D Stock Options (Right to Buy) $ 108.49 ( 5 ) 08/07/2022 Common Stock 95,346 95,346 D Stock Options (Right to Buy) $ 108.49 ( 5 ) 08/07/2022 Common Stock 79,517 79,517 D Stock Options (Right to Buy) $ 106.59 ( 5 ) 08/18/2023 Common Stock 154,169 154,169 D Stock Options (Right to Buy) $ 106.59 ( 6 ) 08/18/2023 Common Stock 102,779 102,779 D Restricted Stock Units ( 7 ) ( 8 ) ( 8 ) Common Stock 21,291 21,291 D Stock Options (Right to Buy) $ 125.05 ( 8 ) 08/09/2024 Common Stock 117,342 117,342 D Stock Options (Right to Buy) $ 125.05 ( 9 ) 08/09/2024 Common Stock 78,228 78,228 D Restricted Stock Units ( 7 ) ( 10 ) ( 10 ) Common Stock 16,918 16,918 D Stock Options (Right to Buy) $ 177.32 ( 10 ) 08/08/2025 Common Stock 90,334 90,334 D Stock Options (Right to Buy) $ 177.32 ( 11 ) 08/08/2025 Common Stock 60,222 60,222 D Restricted Stock Units ( 7 ) ( 12 ) ( 12 ) Common Stock 16,937 16,937 D Stock Options (Right to Buy) $ 190.41 ( 12 ) 08/07/2026 Common Stock 85,725 85,725 D Stock Options (Right to Buy) $ 190.41 ( 13 ) 08/07/2026 Common Stock 57,150 57,150 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kummeth Charles R. 614 MCKINLEY PLACE NE MINNEAPOLIS, MN55413 X Chief Executive Officer Signatures /s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed. 12/27/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes (i) 4,732 shares of restricted stock for which the risk of forfeiture will lapse on August 9, 2020; (ii) 7,519 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2020 and as to 3,759 shares on August 8, 2021; and (iii) 11,291 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on each of August 7, 2020 and August 7, 2021 and as to 3,763 shares on August 7, 2022. ( 2 )The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019. ( 3 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.28, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 4 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.00 to $222.86, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 5 )Fully exercisable. ( 6 )Options to purchase 25,695 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 25,695 shares vest on 8/18/2020. ( 7 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. ( 8 )Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 9 )Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021. ( 10 )Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 11 )Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022. ( 12 )Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 13 )Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.